electroCore (ECOR) investor relations material

Business overview and growth

• Focuses on bioelectronic technology for chronic pain, with FDA-cleared products for headaches and fibromyalgia.

• Achieved over 50% compounded annual revenue growth in the past five years, reaching $32 million in 2025.

• Gross profit margins increased from low 70s to 87% in Q1 2026.

• Largest customer is the VA, with significant opportunity for expansion in federal health systems.

• Leadership changes include a new COO with federal sales expertise.

Product portfolio and innovation

• Flagship gammaCore Sapphire device drives 70% of revenue, primarily sold to the VA.

• Acquired NeuroMetrix and its Quell product for fibromyalgia, growing monthly revenue from $50,000 to $400,000 post-acquisition.

• General wellness products, including Truvaga, leverage influencer partnerships for efficient direct-to-consumer sales.

• TAC-STIM, developed with Air Force Research Labs, targets cognitive performance and military use.

• Platform technology enables expansion into multiple indications, including PTSD, mTBI, and chemotherapy-induced neuropathy.

Market strategy and partnerships

• On contract and formulary with Kaiser Permanente, opening doors to broader insurance coverage.

• Pursuing opportunities in TRICARE, Optum Health, Humana, and federal workers comp.

• Active collaborations with influencers and celebrities, such as Miranda Kerr, to boost product visibility and sales efficiency.

• Efficiency ratio for media spend improved to $2.25 revenue per $1 spent in Q1 2026.